These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 15288287)

  • 1. LH-RH agonists offer very good protection against the adverse gynaecological effects induced by tamoxifen.
    Berlière M; Galant C; Marques G; Piette P; Duck L; Fellah L; Donnez J; Machiels JP
    Eur J Cancer; 2004 Aug; 40(12):1855-61. PubMed ID: 15288287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.
    Sverrisdóttir A; Fornander T; Jacobsson H; von Schoultz E; Rutqvist LE
    J Clin Oncol; 2004 Sep; 22(18):3694-9. PubMed ID: 15365065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status.
    Vehmanen L; Elomaa I; Blomqvist C; Saarto T
    J Clin Oncol; 2006 Feb; 24(4):675-80. PubMed ID: 16446340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: current role and future perspectives.
    Del Mastro L; Levaggi A; Giraudi S; Pronzato P
    Cancer Treat Rev; 2011 May; 37(3):208-11. PubMed ID: 20724078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A case of a premenopausal woman with advanced breast cancer treated with aromatization inhibition in combination with luteinizing hormone-releasing hormone agonist].
    Hisamatsu K; Iwamori S; Minami K; Tanabe K; Ota K; Akiyama H
    Gan To Kagaku Ryoho; 1997 Aug; 24(10):1327-30. PubMed ID: 9279354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian cysts in tamoxifen-treated women with breast cancer.
    Inal MM; Incebiyik A; Sanci M; Yildirim Y; Polat M; Pilanci B; Nayki C; Camuzcuoğlu H
    Eur J Obstet Gynecol Reprod Biol; 2005 May; 120(1):104-6. PubMed ID: 15866095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women.
    Parton M; Smith IE
    J Clin Oncol; 2008 Feb; 26(5):745-52. PubMed ID: 18258982
    [No Abstract]   [Full Text] [Related]  

  • 8. Histopathologic behavior of endometrial hyperplasia during tamoxifen therapy for breast cancer.
    Garuti G; Cellani F; Centinaio G; Sita G; Nalli G; Luerti M
    Gynecol Oncol; 2006 May; 101(2):269-73. PubMed ID: 16297970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
    Gnant MF; Mlineritsch B; Luschin-Ebengreuth G; Grampp S; Kaessmann H; Schmid M; Menzel C; Piswanger-Soelkner JC; Galid A; Mittlboeck M; Hausmaninger H; Jakesz R;
    J Clin Oncol; 2007 Mar; 25(7):820-8. PubMed ID: 17159195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer.
    Rossi E; Morabito A; De Maio E; Di Rella F; Esposito G; Gravina A; Labonia V; Landi G; Nuzzo F; Pacilio C; Piccirillo MC; D'Aiuto G; D'Aiuto M; Rinaldo M; Botti G; Gallo C; Perrone F; de Matteis A
    J Clin Oncol; 2008 Jan; 26(2):264-70. PubMed ID: 18086795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary results on safety and activity of a randomized, double-blind, 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women.
    Guerrieri-Gonzaga A; Robertson C; Bonanni B; Serrano D; Cazzaniga M; Mora S; Gulisano M; Johansson H; Formelli F; Intra M; Latronico A; Franchi D; Pelosi G; Johnson K; Decensi A
    J Clin Oncol; 2006 Jan; 24(1):129-35. PubMed ID: 16382122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic breast lobular carcinoma involving tamoxifen-associated endometrial polyps: report of two cases and review of tamoxifen-associated polypoid uterine lesions.
    Houghton JP; Ioffe OB; Silverberg SG; McGrady B; McCluggage WG
    Mod Pathol; 2003 Apr; 16(4):395-8. PubMed ID: 12692205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of premenopausal patients with advanced or recurrent breast cancer by chemical ablation].
    Sun Q; Huang HY; Zhou YD; Mao F; Yang YQ; Xing Y
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Feb; 25(1):60-2. PubMed ID: 12905610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hormone therapy in breast cancer: the end of tamoxifen?].
    Delozier T
    Bull Cancer; 2005 Feb; 92(2):142-50. PubMed ID: 15749643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polypoid endometriosis and other benign gynaecological complications associated with Tamoxifen therapy-a case to illustrate features on magnetic resonance imaging.
    Kraft JK; Hughes T
    Clin Radiol; 2006 Feb; 61(2):198-201. PubMed ID: 16439226
    [No Abstract]   [Full Text] [Related]  

  • 16. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.
    Swerdlow AJ; Jones ME;
    J Natl Cancer Inst; 2005 Mar; 97(5):375-84. PubMed ID: 15741574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short term results from GHRH analogue use in pre-menopausal breast cancer in Korea.
    Kim HJ; Lee JS; Park EH; Lim WS; Sei JY; Koh BS; Son BH; Ahn JH; Jeong KH; Kim SB; Ahn SH
    Eur J Surg Oncol; 2009 Sep; 35(9):936-41. PubMed ID: 19269125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma.
    Recchia F; Saggio G; Amiconi G; Di Blasio A; Cesta A; Candeloro G; Rea S
    Cancer; 2006 Feb; 106(3):514-23. PubMed ID: 16388519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes on bone mineral density after adjuvant treatment in women with non-metastatic breast cancer.
    Rodríguez-Rodríguez LM; Rodríguez-Rodríguez EM; Oramas-Rodríguez JM; Santolaria-Fernandez F; Llanos M; Cruz J; Martínez A; González-Reimers E; Gómez A; Batista N
    Breast Cancer Res Treat; 2005 Sep; 93(1):75-83. PubMed ID: 16184462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen.
    Kesim MD; Aydin Y; Atis A; Mandiraci G
    Climacteric; 2008 Jun; 11(3):252-7. PubMed ID: 18568790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.